ICYMI: We are encouraged our phase 1a/1b study of #botensilimab (novel innate/ adaptive immune activator) + balstilimab (anti-PD-1-antibody) shows promise in heavily pretreated patients with #MSSCRC. #GI23
We are excited to announce the grand opening of our new fully integrated manufacturing facility at Emeryville, CA on January 17th. Stay tuned for more!
Join us today as Agenus' Senior Director, Head of Drug Discovery, @dhanschand speaks today on the topic of Enhanced CTLA-4 Blockade alongside fellow industry leaders, and SITC series co-chairs James P. Allison and Alan J. Korman. https://t.co/rmTgaOFnY7
Agenus to Host “The Road Taken” R&D Event on November 12, 2022. Featured speakers include @ODayMD, @breelynwilkyMD, Dr. Michael Atkins, and more!
https://t.co/l3PybHLfHH
We are proud to announce that the first patient has been dosed in the Phase 1 study of AGEN1571, our wholly owned ILT2 antibody. AGEN1571 is part of our growing portfolio of clinical assets that are designed to broaden the promise of cancer immunotherapy. https://t.co/VJNloiCiGG
To hear a deeper dive of the remarkable data and implications for the path forward, join @DrElkhoueiry , @DrMhidalgo, Heinz-Josef Lenz and myself today at 10am EST for our post-presentation webcast. #ESMOGI
https://t.co/VJbKZcwWpI
Less than a week away from @ESMOWorldGI in Barcelona! @DrElkhoueiry will be sharing clinical data on botensilimab & balstilimab in MSS CRC in a late-breaking oral session on June 29th. #WCGIC2022. More info at: https://t.co/wg8xuufqvH
Excited to join the @Agenus_Bio Webcast on ESMO GI data. We will be hosting this webcast on June 29th at 10 AM ET following our presentation of clinical data on botensilimab in MSS #colorectalcancer at @ESMOWorldGI. Stay tuned for registration info! #WCGIC2022
Agenus’ CEO @garo_armen and CMO @ODayMD participated in a fireside chat at last week’s Jefferies Healthcare Conference in New York City. Listen in here: https://t.co/E2qaB0K32a
Excited to share that @Jenniferbuell, CEO at MiNK Therapeutics, has been named #15 on @FastCompany & @Lesbiantech’s Annual #FCQueer50 list! Jen inspires me each day as we work side by side in our fight against cancer by harnessing the power of the immune system! Congratulations!
In celebrating #pridemonth we are excited to announce our CEO, @jbuell01, was named #15 on @FastCompany & @lesbiantech’s 3rd Annual #FCQueer50 list!
"Jennifer has always encouraged her employees to be their most authentic selves at work." Check out more: https://t.co/k04vDVgb0v
Beyond excited to announce 3 new clinical collaborations with @targovax, @oxfordbio & @ImmunoGenesis_. These partnerships offer combo's that may unlock the power of immunotherapy more broadly & potentially offer promising benefit to patients with treatment resistant solid tumors.
My long time-time colleagues Michael Atkins (@LombardiCancer) & @ProfGLongMIA (MIA) will be giving 2 of 4 Plenary Abstracts this weekend at @ASCO. Michael is presenting melanoma data on DREAMseq IO vs BRAF/MEK sequencing, and Georgina updates on Rela+Nivo vs Nivo! Stay Tuned!